These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1437254)

  • 1. The role of calcitonin treatment in postmenopausal osteoporosis.
    Wallach S
    Orthop Rev; 1992 Sep; 21(9):1034-42, 1130-1. PubMed ID: 1437254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies against calcitonin.
    Grauer A; Reinel HH; Ziegler R; Raue F
    Horm Metab Res; 1993 Sep; 25(9):486-8. PubMed ID: 8225203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of antibodies against calcitonin.
    Grauer A; Ziegler R; Raue F
    Exp Clin Endocrinol Diabetes; 1995; 103(6):345-51. PubMed ID: 8788305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin.
    Silverman SL
    Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis.
    Papadokostakis G; Damilakis J; Mantzouranis E; Katonis P; Hadjipavlou A
    Eur Spine J; 2006 Mar; 15(3):356-62. PubMed ID: 16193299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain.
    Ofluoglu D; Akyuz G; Unay O; Kayhan O
    Clin Rheumatol; 2007 Jan; 26(1):44-9. PubMed ID: 16575494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The analgesic role of calcitonin following osteoporotic fracture.
    Silverman SL; Azria M
    Osteoporos Int; 2002 Nov; 13(11):858-67. PubMed ID: 12415432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis.
    Muff R; Dambacher MA; Fischer JA
    Osteoporos Int; 1991 Feb; 1(2):72-5. PubMed ID: 1790395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of neutralizing antibodies after treatment with human calcitonin.
    Grauer A; Reinel HH; Lunghall S; Lindh E; Ziegler R; Raue F
    Am J Med; 1993 Oct; 95(4):439-42. PubMed ID: 8213878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis].
    Isaia GC; Di Stefano M; Sciolla A; Mussetta M; Vassellatti D
    Minerva Med; 1995 Mar; 86(3):101-4. PubMed ID: 7603605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.
    Dursun N; Dursun E; Yalçin S
    Int J Clin Pract; 2001 Oct; 55(8):505-9. PubMed ID: 11695068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and treatment of osteoporosis in women with breast cancer.
    Mincey BA; Moraghan TJ; Perez EA
    Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indications and limitations of non-hormonal treatments of osteoporosis].
    Avouac B
    Rev Fr Gynecol Obstet; 1993; 88(7-9):419-23. PubMed ID: 8235256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis syndromes: patient selection for calcitonin therapy.
    Avioli LV
    Geriatrics; 1992 Apr; 47(4):58, 61-4, 67. PubMed ID: 1555780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin and the treatment of osteoporosis.
    Schneyer CR
    Md Med J; 1991 Jun; 40(6):469-73. PubMed ID: 1861574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes].
    Overgaard K; Ravn P; Hansen MA; Christiansen C
    Ugeskr Laeger; 1993 Aug; 155(31):2387-91. PubMed ID: 8346588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis.
    Hizmetli S; Elden H; Kaptanoglu E; Nacitarhan V; Kocagil S
    Int J Clin Pract; 1998 Oct; 52(7):453-5. PubMed ID: 10622084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis.
    Cranney A; Tugwell P; Zytaruk N; Robinson V; Weaver B; Shea B; Wells G; Adachi J; Waldegger L; Guyatt G;
    Endocr Rev; 2002 Aug; 23(4):540-51. PubMed ID: 12202469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.